Cargando…

Effects of the Proteasome Inhibitor Bortezomib in Combination with Chemotherapy for the Treatment of Mantle Cell Lymphoma: A Meta-analysis

OBJECTIVE: The efficacy and the safety of bortezomib-based chemotherapy were characterized in mantle cell lymphoma (MCL) patients. MATERIALS AND METHODS: The PubMed, Cochrane Library, Clinical Key, Science Direct, Oxford Journals, and China National Knowledge Internet databases were searched up to 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Shi-Jun, Hao, Jian, Mao, Yu, Si, Yu-Ling
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7057744/ https://www.ncbi.nlm.nih.gov/pubmed/31464119 http://dx.doi.org/10.4274/tjh.galenos.2019.2019.0128

Ejemplares similares

The effectiveness and harms of bortezomib in combination with chemotherapy for mantle cell lymphoma: A protocol for systematic review and meta-analysis
por: Wang, Xiaoxia, et al.
Publicado: (2020)

Arsenic trioxide rewires mantle cell lymphoma response to bortezomib
por: Zhao, Ling-Ling, et al.
Publicado: (2015)

Bortezomib in mantle cell lymphoma: comparative therapeutic outcomes
por: Vallumsetla, Nishanth, et al.
Publicado: (2015)

Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma
por: Leshchenko, Violetta V., et al.
Publicado: (2015)

The resistance mechanisms of proteasome inhibitor bortezomib
por: Lü, Shuqing, et al.
Publicado: (2013)

The effect of Bortezomib and Rapamycin on Telomerase Activity in Mantle Cell Lymphoma
por: Uziel, Orit, et al.
Publicado: (2014)

Synergistic suppression of the PI3K inhibitor CAL-101 with bortezomib on mantle cell lymphoma growth
por: Qu, Fu-Lian, et al.
Publicado: (2015)

Inhibition of Lyn is a promising treatment for mantle cell lymphoma with bortezomib resistance
por: Kim, Areumnuri, et al.
Publicado: (2015)

Proteasome inhibitor bortezomib enhances the effect of standard chemotherapy in small cell lung cancer
por: Taromi, Sanaz, et al.
Publicado: (2017)

Evaluation of Bortezomib-BeEAM (2BeEAM) as Chemotherapy Regimen Prior to ASCT in Patients with Mantle Cell Lymphoma
por: Huwyler, Fabrizio, et al.
Publicado: (2023)

Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy
por: Boccadoro, Mario, et al.
Publicado: (2005)

Proteasome Inhibitor Bortezomib Ameliorates Intestinal Injury in Mice
por: Yanaba, Koichi, et al.
Publicado: (2012)

Alterations of the Intracellular Peptidome in Response to the Proteasome Inhibitor Bortezomib
por: Gelman, Julia S., et al.
Publicado: (2013)

Case reports: combination therapy with proteasome inhibitor Bortezomib and humanized anti-CD25 Basiliximab for treatment of adult T cell leukaemia lymphoma
por: Kagdi, Huseini, et al.
Publicado: (2014)

Prevalence of bortezomib-resistant constitutive NF-kappaB activity in mantle cell lymphoma
por: Yang, David T, et al.
Publicado: (2008)

Trypanocidal activity of the proteasome inhibitor and anti-cancer drug bortezomib
por: Steverding, Dietmar, et al.
Publicado: (2009)

Metformin Induces Resistance of Cancer Cells to the Proteasome Inhibitor Bortezomib
por: Schlesser, Camille, et al.
Publicado: (2022)

Bortezomib-based therapy for transplant-ineligible East Asian patients with newly diagnosed mantle-cell lymphoma
por: Jin, Jie, et al.
Publicado: (2018)

3-Methyladenine but not antioxidants to overcome BACH2-mediated bortezomib resistance in mantle cell lymphoma
por: Feng, Min, et al.
Publicado: (2021)

Bortezomib Amplifies Effect on Intracellular Proteasomes by Changing Proteasome Structure()
por: Pitcher, David S., et al.
Publicado: (2015)

Effect of the specific proteasome inhibitor bortezomib on cancer‐related muscle wasting
por: Penna, Fabio, et al.
Publicado: (2015)

Cancerous Inhibitor of Protein Phosphatase 2A Mediates Bortezomib-Induced Autophagy in Hepatocellular Carcinoma Independent of Proteasome
por: Yu, Hui-Chuan, et al.
Publicado: (2013)

The Protective Effects of the Proteasome Inhibitor Bortezomib (Velcade) on Ischemia-Reperfusion Injury in the Rat Retina
por: Chen, Fang-Ting, et al.
Publicado: (2013)

Predicting the response of multiple myeloma to the proteasome inhibitor Bortezomib by evaluation of the unfolded protein response
por: Nikesitch, N, et al.
Publicado: (2016)

Bortezomib enhances the anti-cancer effect of the novel Bruton’s tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK
por: Wang, Xianhuo, et al.
Publicado: (2021)

PB2297: PHASE II STUDY OF BORTEZOMIB, CYTARABINE, AND DEXAMETHASONE IN RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA
por: Shin, Junghoon, et al.
Publicado: (2023)

Upregulation of Protein Synthesis and Proteasome Degradation Confers Sensitivity to Proteasome Inhibitor Bortezomib in Myc-Atypical Teratoid/Rhabdoid Tumors
por: Tran, Huy Minh, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Sensitizes AML with Myelomonocytic Differentiation to TRAIL Mediated Apoptosis
por: van Dijk, Marianne, et al.
Publicado: (2011)

Hypoxia Enhances the Senescence Effect of Bortezomib—The Proteasome Inhibitor—On Human Skin Fibroblasts
por: Krętowski, Rafał, et al.
Publicado: (2014)

Overcoming Proteasome Inhibitor-Refractory Multiple Myeloma With Elotuzumab, Bortezomib, Nelfinavir, and Dexamethasone
por: Erath, Alexandra, et al.
Publicado: (2020)

The Proteasome Inhibitor Bortezomib Induces Apoptosis and Activation in Gel-Filtered Human Platelets
por: Ghansah, Harriet, et al.
Publicado: (2021)

Structural basis to repurpose boron-based proteasome inhibitors Bortezomib and Ixazomib as β-lactamase inhibitors
por: Perbandt, Markus, et al.
Publicado: (2022)

Combined systemic and ocular chemotherapy for anterior segment metastasis of systemic mantle cell lymphoma
por: Agarwal, Aniruddha, et al.
Publicado: (2015)

Cost-effectiveness analysis of bortezomib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (VR-CAP) in patients with previously untreated mantle cell lymphoma
por: van Keep, Marjolijn, et al.
Publicado: (2016)

Nelfinavir augments proteasome inhibition by bortezomib in myeloma cells and overcomes bortezomib and carfilzomib resistance
por: Kraus, M, et al.
Publicado: (2013)

Combined Effect of Bortezomib and Menadione Sodium Bisulfite on Proteasomes of Tumor Cells: The Dramatic Decrease of Bortezomib Toxicity in a Preclinical Trial
por: Astakhova, Tatiana M., et al.
Publicado: (2018)

A phase 2 study of rituximab, bendamustine, bortezomib and dexamethasone for first-line treatment of older patients with mantle cell lymphoma
por: Gressin, Rémy, et al.
Publicado: (2019)

Antimalarial activity of the anticancer and proteasome inhibitor bortezomib and its analog ZL(3)B
por: Reynolds, Jennifer M, et al.
Publicado: (2007)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

Analysis of bortezomib inhibitor docked within the catalytic subunits of the Plasmodium falciparum 20S proteasome
por: Sridhar, Settu, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_inhok3ithhegcqjdh6tdvttivg